BETHESDA, Md., June 27, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today announced that Dr. Robert Lodder, Spherix’s President, will present to investors as part of the 7th LHA Life Sciences & Medical Technologies Virtual Conference on Thursday, June 28, 2012 at 11:30 a.m. Eastern Time. The briefing will include the latest update on the planned SPX106T IND submission to the FDA, as well as information on the new SPX723 and SPX100 programs. Opportunities in aneurysm and painful bladder syndrome, new therapeutic areas for Spherix, will also be described.
